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The expression of T  lymphocyte effector functions requires cellular activation. 
Physiologically, these cells are stimulated upon interaction  with specific antigen 
on an appropriate  interacting  second ceil. There are multiple  molecular inter- 
actions that contribute to T  cell activation.  First, the clonotypic T  cell receptor 
interacts with antigen in association with MHC gene products on the surface of 
a target or accessory cell (1-3). This receptor is composed of or- and/3-polypep- 
tides with  Ig-like  structure  and  variability  (4-8).  In  the  human  system,  three 
nonvariable T3 proteins are intimately associated with the antigen  (Ag)~/MHC 
receptor (9-11).  It appears  likely that  murine  T  cells contain  similar proteins; 
however, antibodies to such structures are currently unavailable (12,  13).  Anti- 
bodies directed against the T  cell receptor or T3 (in the human) can activate T 
cells (9,  14).  Second, accessory molecules have been described.  These include 
LFA-1  (15),  L3T4 (16), and Lyt-2 (17); the latter two appear to correlate with 
the class of MHC molecules for which the T  cell is specific (6, 18, 19). Antibodies 
against  these structures  do not activate,  and  it is currently  thought  that  these 
molecules contribute to cellular interactions,  possibly by increasing their avidity 
(6, 20).  It appears that these molecules do not play an obligatory role in T  cell 
activation  (20,  21).  Third,  exogenous  and/or  endogenous  cytokines  may  be 
required.  For T  inducer cells, monokines may be required in addition to T  cell 
receptor triggering  for production  of IL-2 and/or  IL-2-R (22-24).  Interaction 
of IL-2 with its receptor, the latter of which requires activation for expression, 
drives  the  cell  into  cycle (25).  Finally,  other  membrane  molecules have  been 
described on human T  cells whose role is less well defined (e.g., T-11  [26] and 
9.3 [27]). Murine homologues of these proteins have not been identified. Gunter 
et al. have observed that some mAbs against murine Thy-1 activate T  cells (28). 
During  the  course of studies  analyzing  the  activation  of murine  inducer  T 
cells,  we  have  identified  a  novel  T  cell  membrane  antigen,  T  cell-activating 
protein (TAP). Antibodies directed against this molecule can directly activate T 
cells or influence their antigen-specific stimulation. The structure and expression 
of this protein is distinct from any of the above, previously described murine cell 
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TABLE  I 
Properties of mAbs 
Molecular 
mAb  Specificity*  Isotype  mass of  Functional effect  j  Reference 
antigen* 
kD 
3A7  TAP  lgG2a  12  Activating  This report 
1  E7  TAP  IgG2b  12  Inhibitory  This report 
1  A8  TAP  IgG 1  N D  Activating  This report 
2D7  TAPa  IgM  16  None  This report 
1H 12  TAPx  IgG2a  N D  None  This report 
M5/49 ~r  Thy-  1  IgG2a  28  None  29 
H013:4  Thy-l  IgM  28  None  30 
t 1,4.1  H-2K  k  IgG2a  45/12  None  31 
M 1/42 N  H-2  IgG2a  45/12  None  32 
MKD6  I-A  a  IgG2a  34/28  None  33 
3JP  I-A  b  IgG2  34/28  None  34 
10.2.16  I-A  k  IgG2b  34/28  None  31 
HDP1 ~  TNP  IgG1  --  None  I 
* 1H 12 is referred to as anti-TAPx to indicate that its specificity has not been assigned to either the 
TAP or TAPa protein.  1AS  is tentatively  assigned as anti-TAP on the basis of crossblocking, 
pattern of expression, and its functional effects. 
Reported  as nonreduced for the TAP molecule. ND, not determined. 
The anti-la mAbs inhibit T  cell activation  if they  are directed against  the  Ia molecule that is 
corecognized by the T cell. For the experiments in this report they are used as isotype controls of 
irrelevant specificity and are therefore indicated as having no functional effect. 
I Rat mAb. 
i Drs. H. Urnovitz and R. Lynch, University of Iowa, unpublished data. 
surface  antigens.  The  characterization  of  the  structure  and  function of  this 
molecule is the subject of this report. 
Materials and  Methods 
Animals.  C57BL/10, B10.D2, B10.BR, SJL, C3H/Hej, AKR, A/J, CXAFI, and CXBD 
mice ages  5-7  wk  were  purchased  from  The Jackson  Laboratory,  Bar  Harbor,  ME. 
BALB/c AnN were purchased from Charles River Breeding Laboratories, Inc., Wilming- 
ton, MA. B10.AQR mice were bred in our animal colony. 
Animals used in this study we~'e maintained in accordance with the guidelines of the 
Committee  on  Animals of  the  Harvard  Medical  School  and  those  prepared  by  the 
Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal 
Resources,  National  Research  Council (Department  of  Health  and  Human  Services, 
National Institutes of Health, publication 78-23, revised 1979). 
Monoclonal  Antibodies.  The  mAbs  employed  in  this  report  are  listed  in  Table  I 
and/or below. The anti-TAP/TAPa mAbs were generated as follows: CXAF~ mice were 
hyperimmunized with  CXBD  T  cells  and  their sera  were  subsequently screened  for 
functional effects on RF26.12, a B 10 anti-I-E  d specific T  cell hybridoma. Of 23 mice thus 
analyzed, 8  produced sera of varying titers that activated this T  hybrid clone. A single 
mouse whose activating antibody titer was > 1:1,600 was selected for fusion. 20 X  10' T 
cells were injected intravenously and intraperitoneally, and 3  d  later splenocytes were 
harvested and fused with NSI myeloma cells by standard techniques (35). The resultant 
B cell hybridomas were screened for the ability of their supernatant to activate and/or 
bind to RF26.12. Positive wells were expanded and cloned by limiting dilution. The Ig 
isotypes were determined by Ouchterlony analysis with heavy chain-specific  antisera. The 
remainder of the mAbs listed in Table I were kindly made available by the laboratories ROCK  ET  AL.  317 
that developed them as referenced, as were anti-L3T4  (GK1.5) (16),  14.4.4S  (anti-Ia  7) 
(36),  M5/114  (anti-Ia  d) (37),  and anti-Lyt-2.2 (ADH.4) (38).  mAb containing ascites or 
culture supernatant was prepared as previously described (39). Where indicated, antibody 
was purified from culture supernatant on a  protein  A-Sepharose column, or for IgM 
mAbs, by two saturated ammonium sulfate precipitations. The purified 3JP was provided 
by Dr. Man-Sun Sy, Harvard Medical School. 
Immunofluorescence.  Protein A-Sepharose-purilied anti-TAP mAb and affinity-puri- 
fied rabbit anti-mouse Ig (RAMG) were conjugated with FITC and 25 #! of 100 #g/ml 
was used per 106 cells. A  1:90 dilution of rat anti-mouse IgG2 mAb ascites (New England 
Nuclear,  Boston,  MA) and a  1:20  dilution  of FITC goat anti-rat  Ig, not crossreactive 
with mouse Ig (Kirkegaard and Perry Laboratories, Inc., Gaithersburg,  MD) were also 
added at 25 #1 per 106 cells. All incubations were performed at 0°C for 45 min followed 
by three washes. The precise sequence and combination of reagents are detailed in the 
individual experimental legends.  For crossblocking experiments, the cell samples were 
preincubated with an unlabeled mAb for 45 rain at 0°C, washed, then stained as indicated 
in the legend to Fig. 1. After staining all samples were fixed with  1% paraformaldehyde 
and analyzed on a FACS If. 
Immunoprecipitation.  T  cells were surface labeled with ~51 (1  mCi per 50 ×  106 cells) 
with lactoperoxidase (40).  For metabolic labeling,  150  ×  106 cells were washed twice in 
PBS and resuspended in 40 ml of cysteine-free RMPI 1640 (M. A. Bioproducts, Walkers- 
ville, MD) containing  1 mCi [35S]cysteine (New England Nuclear) and  10% dialyzed FCS 
and were incubated for 18 h at 37 ° C. Immunoprecipitations were performed as described 
by Borst (10, 11). Labeled cells were solubilized with 1% N P40 in 10 mM triethanolamine, 
pH  7.8,  150  mM  NaCI,  1 mM  PMSF,  1 #g/ml leupeptin,  1 #g/ml pepstatin,  1 #g/ml 
chymostatin,  1 ttg/ml antipain,  1 #g/ml TLCK, and  10 mM iodoacetate, and incubated 
at least 45 min at 0 ° C. Labeled extracts were centrifuged at 15,000 g for 15 min followed 
by 100,000 g for 45 min. Labeled supernatants were precleared sequentially with fixed 
Staphylococcus Cowen strain I (The Enzyme Center, Boston, MA) for 18 h, three 45-min 
incubations with RAMG-normal mouse Ig preformed immune complexes, followed by 45 
rain with fixed Staphylococcus; all incubations were at 0°C. The precleared extracts were 
then incubated with preformed RAMG-mAb or control Ig complexes for 2 h at 0°C after 
which complex-bound material was pelleted and recentrifuged through a discontinuous 
sucrose-detergent gradient (10). The immunoprecipitated samples were analyzed by SDS- 
PAGE as described by Laemmli (41). Gels with 35S-labeled samples were incubated w~th 
enlightening (New England Nuclear). Autoradiograms were exposed with an intensifying 
screen for 1-3 d at -70°C. 
Cell Preparations and Cell Lines.  Splenocytes were depleted of RBC by treatment with 
Tris-NH4CI. T  cells were enriched by nylon wool fractionation (42). T  cells were depleted 
by incubation with a cocktail of 240 #g H013.4 (anti-Thy-1.2), 1.5 ml GK 1.5 supernatant 
(anti-L3T4), and 0.5 ml ADH4 supernatant (anti-Lyt-2.2) per  10 s RBC free splenocytes 
for 30  min at  0°C,  followed by  1 mi of 1:6  complement (Rabbit  Low-Tox, Accurate 
Scientific  Co.,  Hicksville, NY)  for  30  min at  37°C.  Ia-bearing cells were depleted  by 
treatment with 1 ml M5/114 (anti-Ia) per 40 ×  106 T  cells followed by a  1:12 dilution of 
complement as described above. Con A blasts were prepared by culturing 5 ×  106 nylon 
wool-purified T  cells with 5 #g/mi Con A in media (see below) at 37°C for 48 h at which 
time they were adjusted to 106 cells/ml and both rat Con A supernatant (as a source of 
IL-2) and alpha methyl mannoside were added at a concentration of 5% and 20 mg/ml, 
respectively. After an additional 24 h  incubation, T  cell blasts were isolated on a  Ficoll- 
Hypaque gradient.  The following T  cell hybrids are used in this report: RF26.12  (43) 
(B10 anti-I-Ed-specific), RF9.140 (44) (BALB/c anti-GAT +  I-Ad-specific), RF26.98.47 
(43) (B 10 anti-I-Ad-specific), and RF7.24 (45) (BALB/c anti°GAT + I-Ad-specific). These 
hybrid clones are passaged in vitro in DME, supplemented as previously described (23), 
in the absence of other cell types. D10.G.4, an AKR anti-I-A  k +  conalbumin-specific, T 
cell inducer clone was kindly provided by Dr. C. Janeway, Jr., Yale University (14).  The 
B 10.A CH-1 (46) and BALB/c A202J (47) B lymphoblastoid cell lines were obtained from 318  DEFINITION  OF  A  T  CELL-ACTIVATING  PROTEIN 
Dr.  Steve  Herman  (Dana  Farber  Cancer  Institute,  Boston,  MA)  and  Dr. J.  Kappler, 
(National Jewish Hospital, Denver, CO), respectively. 
Cell  Cultures  and  Assays.  Microcultures  with  T  cell  hybridomas  were  prepared  as 
previously described (44, 45).  Briefly, 0.5-2  X  105 T  cell hybrids were cultured with or 
without a  source of accessory cells (1,660 rad x-irradiated splenocytes or A202J ceils) in 
the presence or absence of mAb and/or antigen in duplicate or triplicate in a final volume 
of 200  #1  of RPMI  1640  media supplemented as previously described (23).  GAT was 
purchased  from  Vega  Biotechnologies, Inc.,  Tucson,  AZ.  The  precise constituents  of 
hybrid and normal T  cell cultures are detailed in the respective experimental protocols. 
After 18 h  incubation at 37°C a  100-#1  aliquot of supernatant was harvested, irradiated 
8,000  rad, and assayed for IL-2 content with the HT2  indicator cell line (33, 45).  Data 
are expressed as the mean cpm of label incorporated by 5  x  103 HT2  cells incubated in 
supernatants from duplicate or triplicate cultures as previously described (45). Microcul- 
tures with normal heterogeneous T  cells were similarly constructed with 5  x  105 nylon 
wool-purified, unprimed T  cells cultured with or without mAb in the presence or absence 
of 5 ×  105 1,660 rad x-irradiated RBC free splenocytes or human monocyte IL- 1, purified 
by hydroxy apatite adsorption, gel exclusion chromatography, and cation exchange HPLC 
(2.5-5 x  105 half-maximal U/mg; Collaborative Research, Waltham, MA). Cultures were 
incubated for 48 h at 37°C with 1 #Ci of [3H]thymidine added over the last 5 h of culture, 
unless otherwise indicated. Data are expressed as the mean cpm incorporated by triplicate 
cultures. The SEM for IL-2 and proliferative responses are usually <15%. 
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FmURE  1.  Expression of TAP determinants on lymphoid cells. The following cellapopu]ations 
were prepared for immunofluorescence analysis.  (A) RF26.I 2  is a B I0 anti-I-E -specific T 
cell hybridoma.  (B-D)  Nylon wool nonadherent, RBC-free splenocytes from  the indicated 
strains.  (E) CH-I  is a B ]ymphoblastoid cell line of BI0.A origin. (F) DI0.G4 is a T  inducer 
clone of AKR origin. (G) B I 0.AQR RBC-free splenocytes treated with a cocktail of anti-Thy- 
1, anti-L3T4, and anti-Lyt-2 followed by complement. BI0.AQR T  cells bear TAP (data not 
shown). For staining, I0  cells were incubated for 45 min on ice sequentially with or without 
(g) 100X of the indicated mAb*-containing culture supernatant followed by FITC-RAMG (A- 
D)  or  monoclonal RAT anti-mouse lgG2 followed by FITC anti-RAT  Ig (which  is  not 
crossreactive with mouse Ig) (E-G). The latter combination is employed to circumvent staining 
of Ig receptors on B cells.  FITC-RAMG will stain  B cells and demonstrates the absence of 
such cells from the T cell preparations. Stained samples were analyzed on a FACS II. 
* 3A7, 1E7, and  1A8 -- anti-TAP; 2D7  = anti-TAPa; IHI2 = anti-TAPx; 10.2.16  = anti-I- 
A  k, Thy =  M5/49, Ia =  10.2.16  (anti-I-A  ~) +  14.4.4.S  (anti-IaT). ROCK  ET  AL.  319 
Results 
Generation  of Anti-TAP  mAb.  A  variety  of  anti-T  cell  alioantisera  were 
screened for the ability to modulate murine T  lymphocyte function. To further 
characterize the relevant antibodies and their ligands, we derived B cell hybrids, 
which were screened for the production of mAbs that bound to, and/or caused 
activation of, a T  cell hybrid. Five related mAbs were identified, whose features 
are summarized in Table I. The function and structure of the molecules detected 
by several  of these  mAbs  have  been  analyzed  and  will  be the  subject of this 
report. These antigens have been provisionally termed T  cell-activating protein 
(TAP) and TAP-associated protein (TAPa). 
Expression  of TAP Determinants on T Cells.  The expression of TAP determi- 
nants  on  a  variety  of cell populations  was tested by immunofluorescence  and 
flow fluorocytometry. As illustrated in Fig.  1 A, all of the T  cell hybrids that we 
have examined  (>10)  strongly express these antigens,  as does the thymic lym- 
phoma (BW5147) that was used in the construction of these hybrid clones (data 
not shown). The positive staining observed in this and subsequent experiments 
is specific as it is not observed with or without antibodies of irrelevant specificity 
followed by FITC anti-Ig reagents (Fig.  1 and data not shown). As shown in Fig. 
1 B, -70% of normal splenic T  lymphocytes bear these antigens. Therefore, the 
expression of TAP proteins appears to define a  major T  cell subpopulation.  In 
contrast to the expression of TAP determinants  on a  majority of peripheral  T 
lymphocytes, only a small subpopulation of thymocytes, which are phenotypically 
mature,  are TAP  + (Yeh,  E.  T.  H.,  H.  Reiser, B.  Benacerraf,  and  K.  L.  Rock, 
manuscript submitted for publication). 
In the spleen, TAP antigens appear to be expressed only on T  iymphocytes. 
This is illustrated in Fig. 1 G. In this experiment, T  cell depleted spleen essentially 
fails to stain with anti-TAP mAbs. An anti-Ia mAb, which reacts with B lympho- 
cytes and macrophages, stains the majority of cells in this population and serves 
as a  positive control.  The  expression  of TAP  antigens  on  B  iymphocytes was 
further analyzed with a  B  lymphoblastoid cell line of appropriate  genetic back- 
ground.  As shown in Fig.  1 E, the CH-1  B cell line is not reactive with the anti- 
TAP mAbs, but stains brightly with anti-Ia mAbs. Under identical conditions, a 
normal  (nonbybrid) T  inducer clone stains  intensely with  the anti-TAP  mAbs 
(Fig.  1 F). Taken together, these results suggest that resting B lymphocytes and 
non-B non-T cells either do not express TAP antigens or do so at significantly 
lower  levels  than  T  lymphocytes.  However,  B  lymphocytes can  express  TAP 
determinants after activation (data not shown). Thus, the majority of B cell blasts 
stimulated with LPS for g6 h are stained with the anti-TAP mAbs, providing the 
lymphocytes are  of the  appropriate  genetic  background  (Yeh,  E.  T.  H.,  B. 
Benacerraf, and K. L. Rock, work in progress). 
T  cells from several inbred mouse strains are nonreactive with our anti-TAP 
mAbs. This is illustrated in Fig.  1 D. Lymphocytes from BALB/c, A/J, and C3H 
are not stained with any of the five antibodies (Fig.  1 D, and data not shown). In 
contrast,  T  cells  from  AKR,  SJL,  and  all  C57BL/6  background  mice 
(C57BL/6,  C57BL/10,  and  related  MHC congenics) are  positive (Fig.  1, B-C 
and data not shown). A more complete analysis of the genetics of TAP expression 320  DEFINITION  OF  A  T  CELL-ACTIVATING  PROTEIN 
FIGURE 2.  SDS Page analysis of I~l-labeled TAP molecules. RF26.12 (B10 anti-I-Ed-specific 
T  cell hybrid) was  ~5I surface-labeled with lactoperoxidase. Cells were lysed with  1% NP40. 
Lysates were precleared with fixed staph A followed by three cycles with performed mouse Ig 
immune complexes followed by fixed staph  A.  Lysates were then  immunoprecipitated with 
preformed complexes of: (A) mouse Ig (cIg); (B) 3A7; (C) Thy-1  (M5/49); (D) 2D7. Samples 
were eluted by boiling in SDS buffer and run on a 5-15% SDS-PAGE gel under nonreducing 
conditions. 
FIGURE  3.  Immunoprecipitation of TAP molecules from Con A  blasts.  Con A  blasts  from 
BALB/ (A-C)  or B10.D2  (D-F)  T  cells were  t~5I surface-labeled with  lactoperoxidase and 
handled as described in Fig. 2, except that immunoprecipitated samples were run on an  18% 
polyacrilamide gel. (A, D) clg, (B, E) 3A7, (C, F) Thy-l. ROCK ET  AL.  321 
is in progress and will be reported. The results with these negative strains again 
demonstrate the specificity of the immunofluorescence staining. 
Biochemical Analysis of TAP Antigens.  A  T  cell hybridoma expressing a  high 
level of TAP antigen was chosen as a source of material for structural character- 
ization. This clone was surface labeled with 125I by lactoperoxidase and solubilized 
in NP-40. As shown in Fig. 2, the 3A7 anti-TAP mAb precipitates a major band 
that migrates  with an  apparent  molecular mass of 12 kD on SDS-PAGE under 
nonreducing  conditions.  An identical  band is observed after immunoprecipita- 
tion with the 1  E7 anti-TAP mAb (data not shown). This band and those described 
below are specific as they are not observed in control precipitations with irrele- 
vant  antibody  or  anti-Thy-l.2  (Fig.  2).  Similar  results  have  been  obtained  in 
experiments with normal T  cells. As shown in Fig. 3, 3A7 immunoprecipitates a 
12-kD  protein  from  125I surface-labeled  Con  A  blasts.  This  molecule  is  not 
precipitated from BALB/c Con A blasts, which are genetically nonreactive with 
the  anti-TAP  mAbs.  As  shown,  Thy-1  is  precipitated  from  the  BALB/c cells 
which serves as a  positive control for labeling and  precipitation.  These results 
confirm the specificity of the immunoprecipitations  with 3A7. To further char- 
acterize the TAP molecule and verify that the precipitated material is synthesized 
by the T  cells, we metabolically labeled cells with 35S cysteine. As shown in Fig. 
4,  the  3A7 and  1E7  mAbs specifically precipitate  identically migrating  10-12- 
kD bands,  sometimes resolved as a triplet.  In contrast,  the 2D7 mAb immuno- 
precipitates a distinct  16 kD band sometimes resolved as a doublet. This protein 
is not visualized by 125I labeling (Fig. 2). The molecules identified by the mAbs 
1  A8 and  1H 12 have not yet been characterized.  A  few additional  minor bands 
have been observed in  anti-TAP  immunoprecipitations,  whose significance re- 
quires further  study. The above findings indicate that the mAbs detect at least 
two proteins that are distinguishable by size and differential labeling, which will 
be referred to as TAP (defined by 3A7,  1E7 mAbs) and TAPa (antigen detected 
by 2D7 mAb, which appears to be associated with TAP; see crossblocking below). 
Crossblocking Studies.  To  define  the  relationship  of TAP  epitopes  to  one 
another,  we have examined  the effect of a  saturating  amount  of one antibody 
(unlabeled) on the binding of a second, labeled mAb. As shown in Fig. 5, all five 
mAbs  crossblock  each  other.  All  combinations  of unlabeled  vs.  labeled  anti- 
TAP/TAPa mAbs have been tested and have shown reciprocal inhibition  (data 
not shown). A control antibody of irrelevant specificity (MKD6, anti-I-A  d, IgG2a) 
FIGURE 4.  Metabolic label of TAP  molecules. The  RF26.12 hybrid was incubated with 
[35S]cysteine  (1 mCi/1.5 x  l0  s cells) for 18 h at 37°C and handled as described  in Fig. 2 with 
the indicated mAb complexes. (A) cIg, (B) 3A7, (C) 2D7, (D) 1E7. 322  DEFINITION  OF  A  T  CELL-ACTIVATING  PROTEIN 
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FIGURE  5.  Effect of unlabeled anti-TAP mAb on the binding of other mAbs: crossblocking 
106  T  cell  hybrids (RF26.12,  B10  anti-lEa-specific) were incubated  in  two stages. Stage  1: 
Inhibitor: incubated with (labeled curves) or without (+ curve) 5  #1 of unconjugated mAb in 
the form of ascites at 0°C for 45 rain, followed by 3 washes. Stage 2. Staining: incubated with 
FITC3A7 (A and B), FITC IE7 (C and D), or M1/42 (anti-H2) (E) for 0°C X 45 rain, followed 
by FITC goat anti-rat mAb (E) which is noncrossreactive with mouse lg.  The fluorescence 
profile was analyzed with a  FACS If. The profile without mAb in stage  1 is labeled "+" and 
the profiles with stage 1 mAb ascites are labeled with the source of the ascites: 3A7, 1E7,  1A8 
=  anti-TAP,  1H12  =  anti-TAPx,  2D7  =  anti-TAPa;  MKD6  =  lgG2  anti-IA  d  (irrelevant 
specificity).  Background  staining with  FITC anti-rat  Ig is  shown as the  "Neg" curve.  It  is 
identical to hybrid without antibody or with an irrelevant FITC mAb (data not shown). 
TABLE  II 
Activation of T Cell Hybrids by Anti-TAP mAbs 
Exp.  Hybrid Specificity  mAb*  Specificity  APC  H-2  Antigen 
I  O0 #g/ml  cpm 
1  RF26.12 (BI0  ....  1,689 
anti-l-E  a)  3A7  TAP  --  --  --  89,710 
1A8  TAP  --  --  --  10,821 
1  E7  TAP  --  --  --  1,014 
2D7  TAPa  --  --  --  1,194 
1H12  TAPx  --  --  --  1,190 
3JP  1  -A  b  __  __  l  736 
--  A20  H-2  --  62,568 
2  RF9.140 (B/c  ....  848 
anti-I-A  d +  GAT)  3A7  TAP  --  --  93,748 
3JP  DA  b  --  --  693 
--  A20  H-2  d  --  707 
--  A20  H-2  d  GAT  99,927 
RF26.89.47  (B10  --  TAP  --  --  945 
anti-I-A  d)  3A7  TAP  --  --  54,933 
11.4.1  H-2K  k  --  --  874 
--  BALB/c  H-2  d  --  22,143 
Microcultures were prepared with 1-2 ×  10 n T  cell hybrids with or without the indicated mAb, in 
the presence or absence of a  source of APC (experiments l  and 2,  l05 la  + A20 cells;  experiment 
3,  105 irradiated  splenocytes) and antigen where indicated,  in a  final volume of 200 #l.  Cultures 
were incubated at  37°C for  18  h  at which time a  100-tM aliquot of supernatant was removed x- 
irradiated and assayed for IL-2 content. 
* Exps. 1-2,  1:50 dilution of dialyzed ascites; exp. 3,  1:4 dilution of 3A7 culture supernatant and 10 
ug/ml of purified 11.4.1  antibody. ROCK  ET  AL.  323 
fails to block, and the anti-TAP  mAbs fail to inhibit the binding of an anti-H-2 
(Fig.  5),  anti-L3T4,  or  anti-T  cell  receptor  antibody  (data  not  shown).  These 
results  suggest  a  close  proximity  or  conformational  dependence  of  the 
TAP/TAPa  epitopes.  Given  this  apparent  relationship  on  the  cell surface and 
the similar pattern of expression, we have referred to the distinct protein detected 
by 2D7 as TAP  associated (TAPa). 
Function  of TAP Molecules:  T  Cell Activation by Anti-TAP mAbs.  The impetus 
for the present study was the initial observation that an anti-T cell alloantiserum 
caused T  cell activation. As shown in Table II, two of the anti-TAP mAbs (3A7 
and  1A8)  activate T  cell hybridomas to produce  IL-2. The  3A7  mAb is more 
active than  1A8, and induces maximal activation (equivalent to maximal antigen 
or lectin  responses).  Purified  3A7  mAb is sufficient for stimulation and can be 
active at nanogram amounts (e.g., half-maximal activation at 10 ng/ml), although 
individual  hybrids may differ in the amount of antibody required for activation 
(data not  shown).  This effect is highly specific since  mAbs of the  same isotype 
but of unrelated specificity and/or that bind other T  cell determinants (e.g., anti- 
H-2, anti-Lyt-1, anti-L3T4, or anti-Thy-l.2), fail to stimulate the hybrids (Table 
II and  data  not  shown).  All  T  cell hybrids that  have been examined (>10) are 
activated, irrespective of the T  cells clonotypic specificity (Table II and data not 
shown).  The TAP-positive BW5147  tumor does not produce  IL-2 upon stimu- 
lation with anti-TAP mAbs (data not shown).  This is not surprising as it fails to 
produce IL-2 even upon mitogen stimulation (reference 48 and data not shown). 
However,  the  TAP  antigens  expressed  by the  BW5147  tumor  are  functional 
when introduced into competent cells, since antigen-specific BALB/c (genetically 
TAP-) X BW5147  T  inducer hybrids are activated by 3A7 (Table II). 
TABLE III 
Activation of Normal Heterogeneous T Cells by Anti-TAP mAbs 
Exp.  T cell Strain (TAP)  [3H]Thymidine in- 
(5 x  105)  mAb  Specificity  corporation (cpm) 
1  BI0.D2 (+)  --  3,517 
3A7  TAP  83,644 
1A8  TAP  13,549 
2D7  TAPa  2,085 
2  BI0.D2 (+)  --  3,262 
3A7  TAP  19,185 
1  E7  TAP  2,770 
1H12  TAPx  3,462 
BALB (-)  --  2,265 
3A7  TAP  1,161 
Microcultures were prepared with 5 x  105 nylon wool-passed lymph node from the indicated strains, 
in the presence or absence of mAb as 1:200 dilution of ascites (anti-TAP). In Exp. 2, 5 x  10  s 1,660- 
tad irradiated  RBC and free syngeneic splenocytes were added as a source of accessory cells. Cultures 
were incubated at 37°C for 48 h, and incorporation  of [3H]thymidine was measured over the final 
6-8 h. As a control for the competence of the BALB/c T cells in Exp. 2, they were tested in an MLR 
5  by culturing  with and  without  5  X  10  syngeneic or allogenic irradiated  splenocytes for 96  h. 
[3H]Thymidine incorporation (cpm): no APC, 1,906; syngeneic APC, 6,310; allogeneic APC, 73,541. 324  DEFINITION  OF  A  T  CELL-ACTIVATING  PROTEIN 
TABLE IV 
Accessory Cell]IL-1 Dependence of Anti-TAP Activation of Normal T Cells 
Splenocyte strain 
(5 x  l0 n) (TAP)  Treatment*  mAb 
[SH]Thymidine  incorporation in cells cul- 
tured with: 
Alone  APC  1L-1 
B10.D2 (+)  --  --  1,925  --  I 
--  3A7  9,227  --  -- 
NW anti-la + C'  i  1,998  1,644  3,461 
NW anti-la + C'  3A7  2,879  19,780  33,232 
Microcultures were prepared with spleen cells treated as indicated in the presence or absence of 
mAb as 1:100 dilution of ascites (anti-TAP). Where indicated, 5  x  105  1,660 rad irradiated RBC 
and free syngeneic splenocytes were added as a source of accessory cells. Where indicated, 5 U/ml 
purified  IL-1  were  added.  Cultures  were  incubated  at  37°C  for  48  h  and  incorporation  of 
[3H]thymidine measured over the final 6-8 h. 
* NW, nylon wool passage, anti-Ia +  C' with M5/114. 
As shown in Table II, the other three anti-TAP/TAPa mAbs fail to activate 
T  cell hybridomas. These mAbs have been tested over a wide range of concen- 
tration with identical results. Further, preliminary experiments have not revealed 
stimulatory activity when these nonactivating mAbs are immobilized on Sepha- 
rose beads to increase avidity and crosslinking (data not shown). Similarly, the 
presence  of accessory cells  in  culture  does  not alter  their  behavior  (data  not 
shown). 
We next investigate  d  the effect of the anti-TAP mAbs on normal, heteroge- 
neous T  cells. As shown in Tables III and IV, the anti-TAP mAbs are mitogenic 
for normal T  cells. Several points should be noted. First, the pattern of activity 
is qualitatively identical to that observed with the T  cell hybridomas. Of the five 
anti-TAP/TAPa  mAbs,  only 3A7  and  1A8  are  stimulatory, with  the  former 
inducing a stronger response (Tables III and IV). The degree of proliferation is 
significantly less than observed with an optimal Con A response (data not shown). 
Second, the stimulation is specific; control mAbs, including those that bind the 
T  cell surface (e.g., anti-H-2 and anti-Thy-l.2) do not cause activation (Tables 
III and IV, and data not shown). Also, T  cells genetically nonreactive with the 
anti-TAP mAbs are not activated (Table  III). Third, the assay for activation is 
proliferation, which is measured at 48  h  of culture.  Therefore, the antibodies 
are capable of rapidly driving at least some T  cells into cell cycle. Fourth, the 
activation of normal T  cells may be more complex than for the T  cell hybridomas. 
Thus  when  T  cells  were  rigorously  depleted  of accessory  cells  by  anti-Ia  + 
complement treatment,  they failed to respond to  3A7  stimulation (Table  IV). 
This response is restored by the addition of irradiated accessory cells or highly 
purified  IL-1  (Table  IV).  Taken  together  these  results  clearly generalize  the 
phenomenon of anti-TAP T  cell stimulation. 
Effect of  Anti-TAP mAb on Antigen-specific  T Cell Responses.  To address whether 
the TAP/TAPa  molecules might be involved in physiologic (antigen-specific) T 
cell stimulation, we tested the effect of the mAbs on specific T  cell responses. 
We first asked what effect, if any, the activating anti-TAP mAbs have on such 
responses. As shown in Fig. 6, a suboptimal amount of the activating anti-mAbs ROCK  ET  AL.  325 
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FTaURE  6.  Effect  of activating  anti-TFA  mAbs  on  antigen-specific stimulation  of T  cell 
hybridomas.  Microcultures  were  prepared  105  RF26.98.47"  with or  without the  indicated 
number  of irradiated  BALB/c  (H-2  ~)  or  A/J  (H-2  a) splenocytes (as a  source  of allogeneic 
stimulators)  in  the presence or absence of the  indicated  mAbs (see below).  Cultures  were 
incubated at 37 °C for 18 h at which time an aliquot of supernatant was removed and assayed 
for IL-2 content. B and C are from the same experiment. 
* RF26.98.47  is an alloreactive, I-A  a specific hybridoma, and it does not react with 1-A k (A/J 
=  I-Ak).  3A7,  1:16  (---O---) or  1:4 (l'q) dilution of culture supernatant.  1A8,  1:4 dilution of 
culture supernatant (-----O--). For this preparation, the amount of antibody is not sufficient to 
directly activate.  1E7,  1:4  dilution  of culture  supernatant  (/~).  2D7,  1:4  dilution of culture 
supernatant (XT). 11.4.1, IgG2a, a (anti-H2Kk),  10 #g/ml purified mAb (m). HDP,, IgG 1, (anti- 
TNP mAb), 10 ug/ml purified mAb (A). 
TABLE  V 
• Augmenting Effect of Activating Anti-TAP mAb on an Antigen-specific T Cell Hybrid 
Hybrid (specificity)  B/C  GAT  mAb  Specificity  cpm 
APC 
RF 9.140 (GAT +  LA  d) 
#g/ml 
+  --  --  466 
+  --  1A8  TAP  730 
+  --  M5/49  Thy-1  926 
+  12.5  --  2,842 
+  12.5  1A8  TAP  10,999 
+  12.5  M5/49  Thy- 1  2,228 
+  25  --  •4,840 
+  25  1A8  TAP  20,472 
+  25  M5/49  Thy-I  7,043 
MicroCukures were prepared with 5 x  104 T  cell hybrids and  106 irradiated BALB/c splenocytes (as 
a source of antigen-presenting cells), with or without the indicated limiting amount of antigen, in the 
absence  or  presence  of a  1:4  dilution  of the  indicated  mAb-containing supernatants.  For  this 
preparation,  the concentration of 1A8  mAb is limiting and  insufficient to cause direct activation. 
Cultures were incubated for 18 h at 37 °C at which time an aliquot of supernatant was removed and 
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synergise with stimulation through the T  cell antigen/MHC receptor. Thus, as 
illustrated,  1A8 and  3A7 both decrease the threshold for antigenic stimulation 
and  markedly  increase  responses  of  the  I-Ad-specific,  alloreactive  hybrid, 
RF26.98.47.  This effect requires  receptor stimulation  since it is not observed 
with  stimulators  bearing  the  inappropriate  Ia  molecules  (A/J,  H-2~).  In  this 
experiment a weak enhancement of the 3A7 response (but not  1A8) is observed 
with  higher numbers  of A/J  cells (Fig.  6C).  This latter  finding  may reflect a 
presentational influence; however, its magnitude is modest and not sufficient to 
account for the dramatic effect observed with the appropriate antigen-bearing 
stimulator.  This is further demonstrated  with antigen-specific hybrids since, as 
shown in Table V, both specific antigen and accessory cells are required for the 
antibody effect.  In both of these  experiments, the antibody effect is  on the T 
cell since the BALB/c and A/J presenting cells are genetically nonreactive with 
the anti-TAP mAbs. As shown, several control mAbs fail to affect responses (Fig. 
6, Table V). It should be noted that at similar limiting concentrations, the  1E7 
and  2D7  mAbs  fail  to augment  responses.  Similar results  have been observed 
with  normal  heterogeneous  T  cell  responses  (data  not  shown).  These  results 
indicate that the activating anti-TAP mAbs are capable of positively modulating 
antigen-specific T  cell responses. 
We next examined the effect of the nonactivating  mAbs on antigen-specific 
hybridoma responses.  As just  noted,  at limiting concentration these antibodies 
neither enhance nor inhibit responses. However, at high concentration the  1E7 
anti-TAP  mAb  is  moderately  inhibitory (Table  VI).  This  effect is  specific as 
inhibition  is not  observed with  control antibodies,  including  several  that  bind 
other T  cell membrane proteins.  In this experiment, the locus of inhibition  is 
the T  cell since the accessory cells in culture are genetically unreactive with this 
antibody. In contrast to this finding, the nonactivating mAbs 2D7 and  1H 12 fail 
to affect responses even at high concentration. Therefore, antibody binding to 
the TAPa protein (defined by 2D7) does not interfere with its function, if indeed 
it has  one.  The observed activating,  augmenting,  and  inhibitory effects of the 
TABLE  VI 
Anti-TAP Inhibition  of Antigen-specific T Cell Activation 
Hybrid (specificity)  B/c APC  GAT  mAb  Specificity  cpm 
RF 7.24 (GAT + I-A  d)  +  --  --  --  731 
+  +  --  --  49,852 
+  +  1E7  TAP  7,094 
4-  +  1H 12  TAPx  40,760 
+  +  2D7  TAPa  32,180 
+  +  H013.4  Thy-1  38,166 
+  +  3JP  I-A  b  38,517 
4-  +  M5/49  Tby-1  45,255 
Microcuhures were prepared with 5 × 104 T cell hybrids, 5 X 105 irradiated BALB/c splenocytes  (as 
a source of antigen-presenting cells) with or without 100 #g/ml of GAT in the presence or absence 
of 100  t~g/ml of purified  mAb (except M5/49,  which was added  as a  1:4 dilution  of culture 
supernatant). Cultures were incubated for 18 h at 37°C after which time supernatant was removed 
and assayed for 1L-2 content. ROCK  ET  AL.  327 
anti-TAP mAbs suggest that TAP participates in physiologic antigen-specific T 
cell stimulation. 
Discussion 
The present study was initiated to investigate cell surface proteins involved in 
murine T  cell immune function.  In this report we describe the characterization 
of a  novel  membrane  T  cell-activating  protein  (TAP).  The  TAP  antigen  is 
expressed on ~70% of normal peripheral T  cells and has an allelic polymorphism 
in this expression. All T  cell hybridomas examined bear TAP as does a T  inducer 
cell clone.  Preliminary  experiments suggest that  this molecule is present on all 
T  inducer cells (Yeh, E. T.  H., and K. L. Rock, work in progress). It will be of 
interest to define the characteristics of the 30% of normal T  cells that either lack 
or express low levels of TAP. 
The  structure  of the TAP molecule has been partially characterized.  When 
immunoprecipitated from 125I surface-labeled T  cells it migrates as a  12-kD band 
on SDS-PAGE under nonreducing conditions. Preliminary experiments show an 
increase in molecular mass to ~17-19 kD upon reduction (data not shown). This 
may  reflect  intrachain  disulfide  bonds.  Metabolic  labeling  experiments  have 
confirmed that TAP is a protein synthesized by the T  cells. Two slightly smaller 
bands are also observed by internal  label, which may represent precursors. 
In parallel internal  label experiments, the 2D7 mAb, which was derived from 
the same fusion as the anti-TAP mAbs, precipitates distinct ~ ! 6-kD bands. This 
molecule is not labeled by lactoperoxidase catalyzed iodination and its mobility 
is not altered upon reduction (data not shown). By these criteria,  this protein is 
distinct from TAP. Nevertheless, the 2D7 mAb efficiently crossblocks the bind- 
ing of anti-TAP mAbs to the cell surface and vice versa. The most straightforward 
interpretation  of this  finding  is  that  the  protein  detected  by the  2D7  mAb is 
closely associated with  TAP molecules on the cell surface.  This  point requires 
further  study.  However, on  the basis of these observations,  the  16-kD protein 
has provisionally been labeled TAPa. 
What is the relationship  of the TAP molecule to previously described T  cell 
antigens? It is clearly distinct from the most well-characterized routine differen- 
tiation antigens. Thus, on the basis of cellular expression, allelism, and molecular 
weight,  it  is distinct  from  Thy-1,  Lyt-1,  Lyt-2,  L3T4,  LFA-1,  and  the  T  cell 
receptor (4,  5,  15,  16,  49-51).  The  immunization  from which  the TAP mAb 
was produced should contain  antibodies against  Ly-6 (52).  Presently,  the Ly-6 
locus appears to encode several hematopoietic antigens (53-55).  However, the 
pattern  of cellular  expression  and  the  molecular  structure  of TAP  makes  it 
appear distinct from previously described Ly-6-related molecules (53-57). Stud- 
ies are underway to further analyze the genetics of TAP expression. 
Several of the features of TAP are reminiscent of the human T  cell receptor- 
associated T3  (CD3) molecules (6, %  and  ~), including antibody mediated acti- 
vation and inhibition (6, 9-12). Antibodies directed against murine T3 molecules 
have not been described. However, it appears that murine T  cells have homolo- 
gous structures since they contain a transcriptionally active T3 ~ gene and T  cell 
receptor-associated proteins have been observed under certain  conditions (I 2, 
l 3). Several observations suggest that TAP is not the murine homologue of the 328  DEFINITION  OF  A  T  CELL-ACTIVATING  PROTEIN 
previously described T3  proteins.  Its  molecular weight is significantly smaller 
than either the human proteins or the predicted]observed proteins in the mouse 
(12,  13).  Furthermore, its cell distribution appears distinct as it is not a pan-T 
cell  antigen  and  may be  expressed  on  activated  B  cells.  Thus,  the  available 
evidence suggests that TAP is not a T3 homo[og, although it is possible that it is 
associated with such structures. It should be noted that by similar criteria TAP 
is distinct from other described human T  cell antigens, including proteins with 
which antibody-induced activation has been observed (e.g., T11  [58] and 9.3 
[27]). We conclude that TAP appears to be a novel T  cell membrane antigen. 
The  TAP  molecule is  of particular  interest because antibody  binding  has 
profound functional effects, the most prominant of which is cellular activation. 
In  this  context,  two  points  should  be  noted:  first,  soluble  anti-TAP  mAb  is 
sufficient for activation. Although many antireceptor antibodies require immo- 
bilization to be stimulatory, there is clearly precedence for both soluble anti-B 
and anti-T cell receptor antibodies causing activation (14,  59).  In our system, 
the nonactivating anti-TAP mAb (e.g., IE7) does not become stimulatory upon 
immobilization (preliminary experiments, data not shown). Second, activation of 
most T  cell hybrids appears to require only receptor triggering without other 
second signals (e.g. IL-1). Thus, most T  hybrid clones respond directly to lectins, 
anticlonotypic mAbs, and will function with fixed antigen-presenting cells, pro- 
vided antigen processing has occurred (60,  61).  Therefore, a  direct activating 
effect of soluble antibody is not surprising, and it clearly demonstrates the direct 
triggering potential of this molecule. 
Normal T  cells are also stimulated by anti-TAP mAbs. Addition of 3A7 or 
1A8 anti-TAP mAbs to cultures of heterogeneous T  cells results in a  modest, 
but significant proliferative response. This observation generalizes the activating 
property of the TAP molecule. It also demonstrates that anti-TAP mAb stimu- 
lation of T  cells is sufficient to drive T  cells into  cell cycle. This response of 
normal T  cells, however, requires additional signals provided by either accessory 
cells or purified IL-1.  It appears,  therefore, that the conditions for anti-TAP 
stimulation are similar to those required for antigen/Ia or lectin stimulation of 
normal T  cells (14, 25, 62, 63). 
Most anti-T cell antibodies are not stimulatory. The ability of anti-TAP mAbs 
to  activate  T  cells  indirectly implies a  receptor/triggering role  for the  TAP 
molecule.  Indeed,  most  well-characterized examples  of  such  effects  involve 
antibodies  directed against  the  physiologic  triggering  structures  (9,  14,  61). 
Therefore, it was of interest to determine whether TAP participates in specific 
immune stimulation. When anti-TAP mAbs are added to cultures of antigen- 
stimulated T  cells, two distinct effects are observed, depending on the mAb. 
First,  the  activating anti-TAP  mAbs (3A7  and  IA8)  synergise with  antigen- 
specific stimulation. This synergy could arise if anti-TAP-TAP is  augmenting 
the function of the T  cell receptor or if it  is generating a  signal that acts  in 
concert with the latter. Our data do not distinguish between these possibilities. 
The nonactivating anti-TAP and anti-TAPa mAbs do not augment responses. 
Second, a nonactivating anti-TAP mAb (1E7) interferes with antigen stimulation 
of T  cell hybrids. Despite having this opposite functional effect, the 1E7  mAb 
appears to react with the same protein as the 3A7 mAb~ There is precedence for ROCK ET  AL.  329 
different mAbs against the same molecule having distinct functional effects (58, 
64, 65). Our data does not distinguish whether this difference is attributable to 
a  property  of the  mAb (e.g.,  affinity or isotype) or the  determinants  that  are 
recognized (e.g., reacting with distinct functional domains on the TAP molecule). 
As  noted,  the  3A7  and  1E7  mAbs  crossblock one  another's  binding.  Taken 
together,  these results  suggest  that  the  TAP  molecule participates  in  immune 
stimulation.  It is possible that TAP participates in the T  cell receptor complex 
or alternatively it might be involved in a distinct molecular triggering event. Our 
data do not distinguish between these or other possibilities. Nevertheless, these 
findings suggest that the membrane molecules involved in T  cell activation may 
be  more  complex  than  previously  described.  In  this  context,  two  points  are 
intriguing.  First,  TAP  could  represent  the  first  example  of a  murine  T  cell 
subset-specific activating protein since it is not detectable on all T  cells. Second, 
the  TAP  molecule  is  expressed  on  phenotypically  and  functionally  mature 
thymocytes but not cortical (double positive) cells, the latter of which can express 
the  T  cell  receptor  but  are  not  responsive  (Yeh,  E.  T.  H.,  H.  Reiser,  B. 
Benacerraf, and  K. L. Rock, manuscript submitted for publication). This raises 
the possibility that TAP expression is involved in the acquisition of immunocom- 
petence.  Future studies will  analyze these points as well as the molecular basis 
for TAPs' functional properties. 
Summary 
Five mAbs have been generated and used to characterize TAP (T cell activating 
protein) a novel, functional murine T cell membrane antigen. The TAP molecule 
is a  12-kD protein  that  is synthesized by T  cells.  By antibody crossbiocking, it 
appears to be closely associated with a  16-kD protein on the T  cell membrane 
also identified with a  novel mAb. These molecules are clearly distinct from the 
major well-characterized murine T  cell antigens previously described. Antibody 
binding to TAP can result in the activation of MHC-restricted, antigen-specific 
inducer T  cell hybridomas that  is equivalent in  magnitude  to maximal  antigen 
or  lectin  stimulation.  This  is  a  direct effect of soluble antibody and  does not 
require accessory cells or other factors. The activating anti-TAP mAbs are also 
mitogenic for normal heterogeneous T  lymphocytes in the presence of accessory 
cells or  IL-1.  In  addition,  these antibodies  are  observed to  modulate  specific 
immune stimulation. Thus, the activating anti-TAP mAbs synergise with antigen- 
specific  stimulation  of T  cells,  while  a  nonactivating  anti-TAP  mAb  inhibits 
antigen  driven  activation.  These  observations  suggest that  the  TAP  molecule 
may participate in physiologic T  cell activation. The possible relationship of TAP 
to known  physiologic triggering  structures,  the T3-T cell receptor complex, is 
considered. TAP is expressed on 70% of peripheral T  cells and therefore defines 
a  major T  cell subset, making it perhaps  the first example of a  murine  subset- 
specific activating protein. 
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Note Added in Proof." The surface JeSl-labeled TAP antigen has recently been resolved as a doublet 
on SDS-PAGE. Preliminary  studies with the 1  A8 and I H 12 mAbs demonstrate that they precipitate 
the 12 kD TAP protein. 
References 
1.  Zinkernagel,  R.  N.,  and  P.  C.  Doherty.  1979.  MHC-restricted  cytotoxic T  cells: 
studies  on  the  biological  role  of polymorphic  major  transplantation  and  antigens 
determining T-cell restriction-specificity, function and responsiveness. Adv. Immunol. 
27:51. 
2.  Schwartz,  R.  H.,  A.  Yano, J.  H.  Stimpfling,  and  W.  E.  Paul.  1978.  Interaction 
between antigen-presenting cells and primed T  lymphocytes. Immunol.  Rev. 40:153. 
3.  Swierkosz, J. E., K. L. Rock, P. Marrack, andJ.  W. Kappler.  1978. The role of H-2 
linked genes in helper T  cell function. II. Isolation on antigen-pulsed macrophages 
of two separate populations of F,  helper T  cells each specific for antigen and one set 
of parental H-2 products. J. Exp. Med.  147:554. 
4.  Allison,J. P., B. W. McIntyre, and D. Block. 1982. Tumor-specific antigen of murine 
T-lymphoma defined with a monoclonal antibody.J. Immunol.  129:2293. 
5.  Haskins,  K., R. Kubo, J. White,  M. Pigeon, J.  Kappler, and P. Marrack.  1983. The 
major histocompatibility complex-restricted antigen receptor on T  cells.  1. Isolation 
with a monoclonal antibody.J. Exp. Med.  157:1149. 
6.  Meuer, S. C., K. A. Fitzgerald, R. B. Hussey, J. C. Hodgdon, S. F. Schlossman, and 
E.  L.  Reinberz.  1983.  Clonotypic structures  involved in antigen-specific  human T 
cell function. Relationship to the T3 molecular complex.J. Exp. Med.  157:705. 
7.  Hedrick,  S.  M.,  D.  I.  Cohen,  E.  A.  Nielson,  and  M.  M.  Davis.  1984.  Isolation of 
cDNA clone encoding T  cell-specific membrane associated proteins. Nature (Lond.). 
308:149. 
8.  Saito, H., D. H. Kranz, Y. Yakagaki, A. C. Hayday, H. N. Eisen, and S. Tonegawa. 
1984. A third rearranged and expressed gene in a clone of cytotoxic T  lymphocytes. 
Nature (Lond. ). 312:36. 
9.  Reinherz, E. L., S. C. Meuer, and S. F. Schlossman. 1983. The human T cell receptor: 
analysis with cytotoxic T  cell clones. Immunol.  Rev. 74:83. 
10.  Borst, J., S. Alexander, J. Elder, and C. Terhorst.  1983. The T3 complex on human 
T  lymphocytes  involves  four  structurally  distinct  glycoproteins.  J.  Biol.  Chem. 
258:5135. 
11.  Borst, J.,  M.  A.  Prendiville,  and  C.  Terhorst.  1983.  The  T3  complex on  human 
thymus-derived  lymphocytes contains  two  different  subunits  of 20  KDa.  Eur.  J. 
Immunol.  13:576. 
12.  Van  de  Elsen,  P.,  B.  A.  Shepley,  M.  Cbo,  and  C.  Terhorst.  1985.  Isolation and 
characterization  of a  cDNA clone encoding the  murine  homologue of the  human 
20K T3/T-cell receptor glycoprotein. Nature (Lond.).  314:542. 
13.  Allison, J.  P.,  and  L.  I.  Lanier.  1985.  Identification  of antigen-receptor-associated 
structures on murine T  cells.  Nature (Lond.).  314:107. 
14.  Kaye, J., S.  Porcelli, J. Tite, B. Jones, and C. Janeway, Jr.  1983. Both a  monoclonal 
antibody and antisera specific for determinants unique to individual cloned helper T 
cell lines can substitute  for antigen and antigen-presenting cells in the activation of 
T  cells.J. Exp. Med.  I58:836. 
15.  Springer,  T. A., D.  Davignon, M.-K.  Ho,  K.  Korzinger, E.  Martz, and  F.  Sancbez- 
Madrid.  1982. LFA-1 and Lyt 2,3, molecules associated with T  lymphocyte-mediated 
killing;  and  Mac  1,  an  LFA-1  homologue  associated  with  complement  receptor 
function. Immunol.  Rev. 68:171. ROCK  ET  AL.  331 
16.  Dialynas,  D.  P.,  D.  B.  Wilde,  P.  Marrack, A.  Pierres,  K. A.  Wall,  W.  Havran,  G. 
Otten, M. R. Loken, M. Pierres, J. Kappler, and F. W. Fitch.  1983. Characterization 
of the marine antigenic determinants, designated L3T4a, recognized by monoclonal 
antibody GK 1.5: expression of L3T4a by functional T cell clones appears to correlate 
primarily with Class II MHC antigen-reactivity. Immunol.  Rev.  74:29. 
17.  Cantor,  H., and E. A. Boyse.  1977.  Lymphocytes as models for the study of mam- 
malian cellular differentiation. Immunol.  Rev.  33:105. 
18.  Meuer, S. F., S. F. Schlossman, and E. L. Reinherz.  1983. Clonal analysis of human 
cytotoxic  T  lymphocytes:  T4+  and  T8+  effector  T  cells  recognize  products  of 
different  major  histocompatibility  complex  regions.  Proc.  Natl.  Acad.  Sci.  USA. 
79:4590. 
19.  Swain, S.  L.  1983.  T  cell subsets and the recognition of MHC class. Immunol.  Rev. 
74:129. 
20.  Marrack,  P.,  R.  Endres,  R. Shimonkevitz, A.  Ziotnik, D.  Dialynas, F.  Fitch, and J. 
Kappler. 1983. The major histocompatibility complex-restricted antigen receptor on 
T  cells.  I1. Role of the L3T4 product.J. Exp. Med.  158:1077. 
21.  Golde, W.,J. W. Kappler, J. Greenstein, B. Mailsen, L. Hood, and P. Marrack. 1985. 
Major histocompatibility complex-restricted antigen receptor on T  cells.  VIII. Role 
of the LFA-1 molecule.J. Exp. Med.  161:635. 
22.  Smith, K. A., L. B. Lachman,J.J. Oppenheim, and M. F. Farata. 1980. The functional 
relationship of the Interleukins. J. Exp. Med.  151 : 1551. 
23.  Rock, K. L.  1982.  The role of Ia molecules in the activation of T  lymphocytes. I. 
The activation of an  IL-1  dependent  IL-2 producing T  cell hybridoma by Con A 
requires an interaction, which is not H-2 restricted with an Ia bearing accessory cell. 
J. Immunol.  129:1360. 
24.  Kaye, J., S. Gillis,  S.  B.  Mizel, E. M.  Shevach, T.  R.  Malek, C. A. Dinarello,  L. B. 
Lachman, and C. A. Janeway, Jr. 1984. Growth of a cloned helper T cell line induced 
by a monoclonal antibody specific for the antigen receptor: Interleukin 1 is required 
for the expression of receptors for Interleukin 2. J. Immunol.  133:1339. 
25.  Moller, G.  1982. Interleukins and lymphocyte activation. Immunol.  Rev. 63:5. 
26.  Howard,  F.  D., J.  A.  Ledbetter, J.  Wong,  C.  P.  Bieber,  E.  B.  Stinson,  and  L.  A. 
Herzenberg. 1981. A human T  lymphocyte differentiation marker defined by mon- 
oclonal antibodies that block E rosette formation. J. Immunol.  126:2117. 
27.  Hara, T.,  S.  M.  Fu,  andJ.  A.  Hansen.  1985.  Human T  cell activation.  II. A  new 
activation pathway used by a  major T  cell population via a disulfide bonded dimer 
of a 44 Kd polypeptide (9.3 antigen).J. Exp. Med.  161:1513. 
28.  Gunter, K. C., T. R. Malek, and E. M. Shevach. 1984. T  cell-activating properties of 
an anti-Thy  1 monoclonal antibody: possible analogy to OKT3/Leu4. J.  Exp. Med. 
159:716. 
29.  Davignon,  D.,  E.  Martz,  T.  Reynolds,  K.  Kurzinger,  and  T.  A.  Springer.  1981. 
Lymphocyte function-associated antigen  1 (LFA-1): a surface antigen distinct from 
Lyt 2,3 that participates in T  lymphocyte mediated killing. Proc. Natl. Acad. Sci. USA. 
78:4535. 
30.  Marshak-Rothstein, A., P. Fink, D. H. Gridley, D. H. Raulet, M.J. Bevan, and M. L. 
Gefter. 1979.  Properties and applications of monoclonal antibodies directed against 
determinants of the Thy 1 locus. J. Immunol.  122:2491. 
31.  oi,  v.,  P.  Jones,  J.  Goding,  L.  A.  Herzenberg,  and  L.  A.  Herzenberg.  1978. 
Properties of monoclonai antibodies to mouse Ig allotypes, H-2 and Ia antigens. Curr. 
Top.  Microbiol. Immunol.  81 : 115. 
32.  Stallcup,  K. C.,  T.  A.  Springer,  and  M.  F.  Mescher.  1981.  Characterization of an 332  DEFINITION OF  A  T  CELL-ACTIVATING PROTEIN 
anti-H-2  monoclonal  antibody  and  its  use  in  large-scale  antigen  purification. J. 
Immunol.  127:923. 
33.  Kappler, J. W., B. Skidmore, J. White, and P. Marrack. 1981. Antigen inducible, H- 
2 restricted, lnterleukin-2 producing T cell hybridomas. Lack of independent antigen 
and H-2 recognition. J. Exp. Med. 153:1198. 
34.  Janeway, C. A., P.J. Conrad, E. A. Lerner, J. Babich, P. Wettstein, and D. B. Murphy. 
1984.  Monocional antibodies specific for Ia glycoproteins raised by immunization 
with  activated  T  cells.  Possible  role  of T  cell  bound  Ia  antigens  as  targets  of 
immunoregulatory T  cells. J. Immunol.  132:662. 
35.  Galfre, G., and C. Milstein.  1981.  Preparation of monoclonal antibodies: strategies 
and procedures. Methods Enzymol. 73:3. 
36.  Ozato, K., N. Mayer, and D. H. Sachs.  1980.  Hybridoma cell lines secreting mono- 
clonal antibodies to mouse H-2 and Ia antigens. J. Immunol.  124:533. 
37.  Bhattacbarya,  A.,  M.  E.  Dorf,  and  T.  A.  Springer.  1981.  A  shared  alloantigenic 
determinant on Ia antigens encoded by the I-A and I-E subregions. Evidence for I 
region gene duplication. J. Immunol.  127:2488. 
38.  Gottlieb, P. D., A. Marshak-Rothstein, K. Auditore-Hargreaves, D. B. Berkober, D. 
A. August, R. M.  Rosche, and J. D. Benedetto.  1980.  Construction and properties 
of new Lyt-congenic strains and anti-Lyt 2.2 and anti-Lyt 3.3 monoclonal antibodies. 
Immunogenetics. 10:545. 
39.  Rock, K. L., and B. Benacerraf. 1974. The role of Ia molecules in the activation of 
T  lymphocytes. V.  Developing T  cells are driven to expand upon interaction with 
Class II MHC gene products on accessory cells. Proc. Natl. Acad. Sci. USA. 81:1221. 
40.  Haustein,  D., J. J.  Marchalonis,  and  A.  W.  Harris.  1975.  Immunoglobulin of T 
lymphoma cells.  Biosynthesis  surface  representation  and  partial  characterization. 
Biochemistry. 14:1826. 
41.  Laemmli, U.  K.  1970.  Cleavage of structural  proteins during the assembly of the 
head of bacteriophage T4. Nature (Lond.). 227:680. 
42.  Julius,  M.  F.,  E.  Simpson, and  L.  A.  Herzenberg.  1973.  A  rapid  method for the 
isolation of functional thymus-derived murine lymphocytes. Eur. J. Immunol.  3:645. 
43.  Rock,  K.  L., and  B.  Benacerraf.  1984.  Selective modification of a  private Ia allo- 
stimulating determinant upon antigen association with an antigen-presenting cell. J. 
Exp. Med. 159:1238. 
44.  Rock, K. L., and B.  Benacerraf.  1983.  Inhibition of antigen-specific T  lymphocyte 
activation by structurally related Ir gene controlled polymers. Evidence of specific 
competition for accessory cell antigen-presentation. J. Exp. Med. 157:1618. 
45.  Rock, K. L., and B. Benacerraf.  1983. The role of Ia molecules in the activation of 
T  lymphocytes. III. Antigen-specific, Ia restricted  Interleukin-2 producing T  cell 
hybridomas with  detectable affinity for the  restricting I-A molecule. J.  Exp. Med. 
157:359. 
46.  Lanier, L., N. L. Warner,J. A. Ledbetter, and L. A. Herzenberg. 1981. Quantitative 
immunofluorescent analysis of surface phenotypes of murine B cell lymphomas and 
plasmacytomas with monoclonal antibodies. J. lmmunol.  127:1691. 
47.  Kim, K. J., C. Kanellopoulos-Langvin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 
1979.  Establishment and  characterization  of BALB/c lymphoma lines with  B cell 
properties. J. Immunol.  122:549. 
48.  Rock, K. L.  1985. Functional T  cell hybridomas. In Hybridoma Technology in the 
Biosciences and Medicine. T. A. Springer, editor, Plenum Press, New York. 527-544. 
49.  Reif, A., andJ.  M. V. Allen.  1964. The AKR thymic antigen and its distribution in 
leukemias and nervous tissue. J. Exp. Med. 120:413. 
50.  Ledbetter,J. A., R. I. Evans, M. Lipinski, C. Cunningham-Rundles, R. A. Good, and ROCK  ET  AL.  333 
L. A. Herzenberg. 1981. Evolutionary conservation of surface molecules that distin- 
guish  T  lymphocyte  helper/inducer  and  cytotoxic/suppressor  subpopulations  in 
mouse and man.J. Exp. Med.  153:310. 
51.  Ledbetter, J. A., and L. A. Herzenberg. 1979. Xenogeneic monocional antibodies to 
mouse lymphoid differentiation antigens, lmmunol. Rev. 47:63. 
52.  McKenzie, I. F.  C.,  M.  Cherry, and G. D. Snell.  1977.  Ly-6.2: a  new lymphocyte 
specificity of peripheral T-ceils. Immunogenetics.  5:25. 
53.  Auchincloss, H.,Jr., K. Ozato, and D. Sachs. 1981. Two distinct murine differentia- 
tion antigens determined by genes linked to the Ly 6 locus. J. Immunol.  127:1839. 
54.  Kimura, S.,  N. Tada, Y. Liu-Lam, and V. Hammerling. 1984. Studies of the mouse 
Lyt-6 alloantigen system. II. Complexities of the Ly-6 region. Immunogenetics.  20:47. 
55.  Hogarth, P.  M., B. A. Houlden, S. E. Lathan, V. R. Sutton, and I. F. C. McKenzie. 
1984.  Definition of new alloantigens encoded by genes in the Ly-6 complex. Immu- 
nogenetics. 20:57. 
56.  Takei, T.  1982. Biochemical characterization of H9/25 an allospecificity encoded by 
the Ly-6 region. Immunogenetics.  16:201. 
57.  Matossian-Rogers, A., P. Rogers, J. Ledbetter, and L. A. Herzenberg. 1982. Molec- 
ular weight determinants of two genetically linked cell surface murine antigens: ThB 
and Ly-6. lmmunogenetics.  15:591. 
58.  Meuer,  S.  C.,  R.  E.  Hussey, M.  Fabbi,  D.  Fox,  O.  Acuto,  K. A.  Fitzgerald, J.  C. 
Hodgdon, J. P. Protentis, S. F. Schlossman, and E. L. Reinberz.  1984. An alternate 
pathway of T  celt activation: a functional role for the 50 Kd T1 t sheep erythrocyte 
receptor protein. Cell. 36:897. 
59.  Parker, D. C., D. C. Wadsworth, and G. B. Schneider.  1980. Activation of murine B 
lymphocytes by anti-immunoglobulin is an inductive signal leading to immunoglob- 
ulin secretion.J. Exp. Med.  152:138. 
60.  Rock, K. L., and B. Benacerraf. 1983. MHC restricted T  cell activation: analysis with 
T  cell hybridomas. Immunol. Rev.  76:29. 
61.  Kappler, J., R. Kubo, K. Haskins, J. White, and P. Marrack. 1983. The mouse T  cell 
receptor: comparison of major histocompatibility restricted receptors on two T  cell 
hybridomas. Cell  34:727, 
62.  Germain, R. N. 1981. Accessory cell stimulation ofT cell proliferation requires active 
antigen  processing,  Ia-restricted  antigen-presentation  and  a separate  nonspecific 
second signaI.J. Immunol.  127:1964. 
63.  DeFreitas, E. C., R. W. Chesnut, H. M. Gery, andJ. M. Chiller.  1983. Macrophage- 
dependent  activation  of antigen-specific  T  cells  requires  antigen  and  a  soluble 
monokine.J. IramunoL  131:23. 
64.  Martin,  P. J.,  G.  Longton, J.  A.  Ledbetter,  W.  Newman,  M.  P.  Beatty, and J.  A. 
Hanson. 1983. Identification and functional characterization of two distinct epitopes 
on the human T  cells surface protein Tp50. J. ImmunoL  131 : 180. 
65.  Krensky, A. M., F. Sanchez-Madrid, E. Robbins, Z. A. Nagy, T. A. Springer, and S. 
D. Burakoff.  1983. The functional significance, distribution, and structure of LFA- 
1, LFA-2 and LFA-3: cell surface antigens associated with CTL-target interactions. 
J. Immunol.  131:611. 